What gets a telehealth company an FDA warning letter
The short answer
Almost always the marketing, not the medicine. The letters sent to telehealth companies since September 2025 cite sentences on websites: calling a compounded drug equivalent to an approved one, calling a pharmacy FDA approved, attributing an approved drug's trial results to a compounded version, and adding an ingredient to justify copying a drug that is no longer in shortage. These are page-level problems with page-level fixes, which is the good news. They are also public and permanent once sent, which is the bad news.
Why the website rather than the pharmacy?
Because the website is what the agency can read without an inspection, and because the claims on it are the brand's own rather than the pharmacy's.
This catches founders out. The assumption is that compounding risk sits with the compounder and the brand is a shopfront. The letters say otherwise: they are addressed to the telehealth company, they quote its pages, and they are published under its name.
It also means the exposure is the half you control. You cannot audit a pharmacy's media fill records from your desk. You can read every sentence on your own product pages this afternoon.
Which sentences, exactly?
Equivalence. Generic, identical, equivalent, the same as, a version of, or naming an approved brand beside your compounded product in a way that implies they are interchangeable.
Borrowed evidence. Quoting the weight-loss percentages or trial outcomes of an approved drug on a page selling a compounded one. The results belong to the product that was studied.
The word approved, anywhere near your supply chain. Compounding pharmacies and outsourcing facilities are not FDA approved or FDA licensed. A compounded drug does not become approved because its active ingredient matches one that is. Both of those are the FDA's own words from a letter.
Add-an-ingredient. Combining a copied drug with a vitamin and presenting that as a meaningful difference. The agency has cited a page offering semaglutide with "a body safe vitamin such as B12" by name.
Anonymous supply. Selling under your own brand and trademark without disclosing which pharmacy actually compounds the product.
What does a letter actually cost?
The response itself is the smallest part. You have fifteen working days to answer, and the answer is usually a corrective plan and a page rewrite.
The durable cost is that the letter is published on the FDA website with your company name, indexed, and findable by anyone who searches you. That includes every payment processor, advertising platform, pharmacy and provider network you depend on, and each of them makes its own decision on its own timetable. A processor re-underwriting you is not an FDA action and does not wait for one.
The second-order cost is that it removes your options exactly when you need them. A brand looking for a new pharmacy partner while holding a published warning letter is negotiating from a much worse position than it was a month earlier.
How do you audit your own pages?
Write the claims list first: the sentences you are allowed to say, and the words that are banned outright. Then hold every product page, email, ad and affiliate page to it. The list is cheap to write once and impossible to apply consistently from memory.
Read the affiliate pages too. A claim made by someone you pay is a claim you made, and affiliate copy is the most common place an outlawed sentence survives a cleanup of the main site.
Dispense Flow runs a compliance check across your store before you publish, which reads your copy for outcome promises, missing safety information and missing policy links. It is a help and not a guarantee, it cannot judge whether a claim is substantiated, and it does not replace a healthcare lawyer reading the store before launch.
Questions
Does a warning letter mean I have to stop selling?
Not automatically. It demands a response and correction. The practical pressure usually arrives from processors, ad platforms and partners who read it and act on their own terms.
How long do I have to respond?
Fifteen working days is the usual window stated in the letter.
Are the letters public?
Yes. They are published on the FDA website with the company name, and they are indexed by search engines.
Is my pharmacy responsible for my marketing claims?
No. The letters are addressed to the telehealth company and quote its own pages. Your pharmacy has its own obligations and they do not cover your website.
Do these rules apply to approved drugs too?
The equivalence and approval claims are specific to compounded products, but FTC substantiation rules apply to every health claim you make about anything.